General Information

General Information

DRAVP ID DRAVPe01730

Peptide Name SARS-CoV (1028–1049)[Y1049W]

Sequence GYHLMSFPQAAPHGVVFLHVTW

Sequence Length 22

UniProt ID Q19QX0

Taxon ID None

Source Synthetic construct

Validation Experimentally Validated

Origin Information

Gene Name/ID Not Available

GenBank Not Available

Amino Acid position Not Available

Domain Accession ID Not Available

Nucleotide sequence ID Not Available

Molecular Type Not Available

Chromosomal Position Not Available

Activity Information

Target Organism SARS-CoV

Assay Plaque reduction assay

Activity

[Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(90% inhibition at 30 μM,IC50~2 μM).

Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity

[Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells

Binding Target cell membrane

Mechanism inhibits viral entry through coiled coil interactions.

Structure Information

PDB ID None

Predicted Structure Download No predicted structure available

Linear/Cyclic Linear

N-terminal Modification Free

C-terminal Modification Free

Other Modification None

Stereochemistry L

Physicochemical Information

Formula C120H166N30O26S

Absent amino acids CDEIKNR

Common amino acids HV

Mass 2607.98

Pl 7.02

Basic residues 3

Acidic residues 0

Hydrophobic residues 10

Net charge 3

Boman Index 1247

Hydrophobicity 45.65

Aliphatic Index 80.43

Half Life

Mammalian:30 hour
Yeast:>20 hour
E.coli:>10 hour

Extinction Coefficient cystines 6990

Absorbance 280nm 317.73

Polar residues 5

Literature Information

Literature 1

Title Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.

Pubmed ID 16616792

Reference Virus Res. 2006 Sep;120(1-2):146-55.

Author Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF.

DOI 10.1016/j.virusres.2006.03.001